Another example is the CheckMate 012 study that combined nivolumab with erlotinib in patients with advanced, EGFR-mutant NSCLC, who were EGFR tyrosine kinase inhibitor (TKI)–naive or TKI-treated, but had not received chemotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.